Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
editorial
. 1992 Mar 28;304(6830):791–792. doi: 10.1136/bmj.304.6830.791

Detecting susceptibility to malignant hyperthermia.

F R Ellis
PMCID: PMC1881639  PMID: 1392703

Full text

PDF
791

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adnet P. J., Krivosic-Horber R. M., Adamantidis M. M., Haudecoeur G., Adnet-Bonte C. A., Saulnier F., Dupuis B. A. The association between the neuroleptic malignant syndrome and malignant hyperthermia. Acta Anaesthesiol Scand. 1989 Nov;33(8):676–680. doi: 10.1111/j.1399-6576.1989.tb02990.x. [DOI] [PubMed] [Google Scholar]
  2. Campkin N. T., Davies U. M. Another death from Ecstacy. J R Soc Med. 1992 Jan;85(1):61–61. [PMC free article] [PubMed] [Google Scholar]
  3. Fujii J., Otsu K., Zorzato F., de Leon S., Khanna V. K., Weiler J. E., O'Brien P. J., MacLennan D. H. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science. 1991 Jul 26;253(5018):448–451. doi: 10.1126/science.1862346. [DOI] [PubMed] [Google Scholar]
  4. Gillard E. F., Otsu K., Fujii J., Khanna V. K., de Leon S., Derdemezi J., Britt B. A., Duff C. L., Worton R. G., MacLennan D. H. A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics. 1991 Nov;11(3):751–755. doi: 10.1016/0888-7543(91)90084-r. [DOI] [PubMed] [Google Scholar]
  5. Healy S. J., Heffron J. J., Lehane M., Bradley D. G., Johnson K., McCarthy T. V. Diagnosis of susceptibility to malignant hyperthermia with flanking DNA markers. BMJ. 1991 Nov 16;303(6812):1225–1228. doi: 10.1136/bmj.303.6812.1225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kalow W., Britt B. A., Terreau M. E., Haist C. Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet. 1970 Oct 31;2(7679):895–898. doi: 10.1016/s0140-6736(70)92069-6. [DOI] [PubMed] [Google Scholar]
  7. Levitt R. C., Nouri N., Jedlicka A. E., McKusick V. A., Marks A. R., Shutack J. G., Fletcher J. E., Rosenberg H., Meyers D. A. Evidence for genetic heterogeneity in malignant hyperthermia susceptibility. Genomics. 1991 Nov;11(3):543–547. doi: 10.1016/0888-7543(91)90061-i. [DOI] [PubMed] [Google Scholar]
  8. MacLennan D. H., Duff C., Zorzato F., Fujii J., Phillips M., Korneluk R. G., Frodis W., Britt B. A., Worton R. G. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature. 1990 Feb 8;343(6258):559–561. doi: 10.1038/343559a0. [DOI] [PubMed] [Google Scholar]
  9. McCarthy T. V., Healy J. M., Heffron J. J., Lehane M., Deufel T., Lehmann-Horn F., Farrall M., Johnson K. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature. 1990 Feb 8;343(6258):562–564. doi: 10.1038/343562a0. [DOI] [PubMed] [Google Scholar]
  10. Renwick D. S., Chandraker A., Bannister P. Missed neuroleptic malignant syndrome. BMJ. 1992 Mar 28;304(6830):831–832. doi: 10.1136/bmj.304.6830.831. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES